November 6, 2018 / 11:35 AM / in 10 days

Drugmaker Lilly's third-quarter profit more than doubles

Nov 6 (Reuters) - U.S. drugmaker Eli Lilly and Co’s third-quarter profit more than doubled, led by higher demand for its newer treatments such as diabetes drug Trulicity and psoriasis medicine Taltz.

Net income rose to $1.15 billion or $1.12 per share in the three months ended Sept. 30, from $555.6 million or 53 cents per share a year earlier, Lilly said on Tuesday.

Lilly’s net income a year earlier was hurt by a write-down expense of more than $400 million.

Revenue rose about 7 percent to $6.06 billion. (Reporting by Aakash Jagadeesh Babu and Tamara Mathias in Bengaluru Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below